Allergy Therapeutics (LON:AGY) Share Price Passes Below Two Hundred Day Moving Average - Should You Sell?

Key Points

• Shares dipped below the 200‑day moving average: the stock fell intraday beneath the 200‑day MA of GBX 10.43, trading as low as GBX 9.50 and last at GBX 10.50 on a volume of 90,479 shares.
• Weak financials and negative earnings: the company reported quarterly EPS of GBX -0.38, a net margin of -85.46%, an extremely high debt‑to‑equity ratio of 629.58, and analysts forecast FY EPS of -2.56.
• Biotech commercial profile: Allergy Therapeutics is an international allergy immunotherapy company with a market cap of £680.75m and a pipeline including grass, tree, house dust mite vaccines and a preclinical peanut vaccine.

Allergy Therapeutics plc (LON:AGY - Get Free Report)'s stock price crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 10.43 and traded as low as GBX 9.50. Allergy Therapeutics shares last traded at GBX 10.50, with a volume of 90,479 shares trading hands.

Allergy Therapeutics Stock Performance

The stock has a market cap of £680.75 million, a PE ratio of -11.08, a price-to-earnings-growth ratio of -30.70 and a beta of 0.91. The company has a debt-to-equity ratio of 629.58, a current ratio of 1.13 and a quick ratio of 1.48. The business has a 50 day moving average price of GBX 10.78 and a two-hundred day moving average price of GBX 10.43.

Allergy Therapeutics (LON:AGY - Get Free Report) last released its quarterly earnings data on Tuesday, March 31st. The company reported GBX (0.38) earnings per share for the quarter. Allergy Therapeutics had a negative net margin of 85.46% and a positive return on equity of 409.00%. The company had revenue of GBX 3,628 million for the quarter. As a group, equities research analysts forecast that Allergy Therapeutics plc will post -2.56 EPS for the current fiscal year.

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.